GLP-1 Weight-Loss Drugs

Novo Nordisk has dismissed its patent-infringement lawsuit against telehealth company Hims & Hers after the two reached an agreement that will put Novo’s branded weight-loss drugs Wegovy and Ozempic on the Hims platform later this month. The legal clash began after Hims announced plans to sell a cheaper, compounded off‑brand version of Wegovy, which Novo denounced as an “unapproved, inauthentic, and untested knockoff” of semaglutide and vowed to sue over. Within days, Hims scrapped the compounded product following an FDA threat to restrict access to the active ingredients used to copy GLP‑1 drugs, highlighting how regulators can choke off the booming gray market that’s sprung up around these medicines. Under the new deal, Hims will stop advertising compounded GLP‑1s and instead sell Novo’s oral and injectable products, while Novo keeps the right to refile its lawsuit if needed. Investors cheered the pivot, sending Hims & Hers shares up more than 36% in Monday morning trading and lifting Novo Nordisk’s U.S.-listed stock about 1.8%, underscoring Wall Street’s view that brand‑name drugmakers and big telehealth platforms are likely to consolidate control over this multibillion‑dollar weight‑loss market.